PedAM
Pediatric Disease Annotations & Medicines
| hydronephrosis | ||||
| Disease ID | 1126 |
|---|---|
| Disease | hydronephrosis |
| Manually Symptom | (Waiting for update.) |
| Text Mined Symptom | UMLS | Name | Sentences' Count(Total Symptoms:16) C0030193 | pain | 10 C0016199 | flank pain | 7 C0041952 | ureteral stone | 6 C0041956 | ureteral obstruction | 6 C0042075 | uropathy | 4 C0014175 | endometriosis | 4 C0426768 | o sign | 2 C0232808 | nonfunctioning kidney | 2 C0020538 | hypertension | 2 C0341697 | impaired renal function | 2 C0005697 | neurogenic bladder | 2 C0079924 | oligohydramnios | 1 C0022660 | acute renal failure | 1 C0162283 | nephrogenic diabetes insipidus | 1 C0020538 | high blood pressure | 1 C1839611 | n syndrome | 1 |
Manually Genotype(Total Text Mining Genotypes:0) |
|---|
| (Waiting for update.) |
All Snps(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Annotation(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Snp Trait(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
Mapped by lexical matching(Total Items:0) |
|---|
| (Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
|---|
| (Waiting for update.) |
Chemical(Total Drugs:9) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
| C0020295 | ciprofloxacin | D002939 | 85721-33-1 | hydronephrosis | MESH:D006869 | marker/mechanism | 10893604 | ||
| C0020295 | cyclophosphamide | D003520 | 50-18-0 | hydronephrosis | MESH:D006869 | marker/mechanism | 10507982 | ||
| C0020295 | fluorouracil | D005472 | 51-21-8 | hydronephrosis | MESH:D006869 | therapeutic | 2996749 | ||
| C0020295 | indinavir | D019469 | 150378-17-9 | hydronephrosis | MESH:D006869 | marker/mechanism | 10069120 | ||
| C0020295 | metoprolol | D008790 | 37350-58-6 | hydronephrosis | MESH:D006869 | marker/mechanism | 8554013 | ||
| C0020295 | midodrine | D008879 | 42794-76-3 | hydronephrosis | MESH:D006869 | marker/mechanism | 17901021 | ||
| C0020295 | mitomycin | D016685 | 1950/7/7 | hydronephrosis | MESH:D006869 | therapeutic | 2996749 | ||
| C0020295 | morphine | D009020 | 57-27-2 | hydronephrosis | MESH:D006869 | marker/mechanism | 12710656 | ||
| C0020295 | phenytoin | D010672 | 57-41-0 | hydronephrosis | MESH:D006869 | marker/mechanism | 18620500 | ||
FDA approved drug and dosage information(Total Drugs:2) | ||||||||
|---|---|---|---|---|---|---|---|---|
| DiseaseID | Drug_name | active_ingredients | strength | Dosage Form/Route | Marketing Status | TE code | RLD | RS |
| MESH:D006869 | cipro | ciprofloxacin | 400MG/40ML (10MG/ML) | INJECTABLE;INJECTION | Discontinued | None | Yes | No |
| MESH:D006869 | cipro | ciprofloxacin | 250MG/5ML | FOR SUSPENSION;ORAL | Prescription | AB | Yes | No |
FDA labeling changes(Total Drugs:2) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiseaseID | Pediatric_Labeling_Date | Trade_Name | Generic_Name_or_Proper_Name | Indications Studied | Label Changes Summary | Product Labeling | BPCA(B) | PREA(P) | BPCA(B) and PREA(P) | Pediatric Rule (R) | Sponsor | Pediatric Exclusivity Granted Date | NNPS |
| MESH:D006869 | 03/25/2004 | cipro | ciprofloxacin | Complicated UTI and pyelonephritis | Indicated for the treatment of complicated urinary tract infections (cUTIs) and pyelonephritis in pediatric patients 1 17 years of age Not drug of first choice due to increased adverse events compared to controls including events related to joints and/or surrounding tissues Information on PK and dose in pediatric patients 1 17 years of age The most frequent adverse events observed within 6 weeks of treatment initiation during the cUTI clinical trial were gastrointestinal 15% compared to 9% and musculoskeletal 9.3% compared to 6% in ciprofloxacin-treated compared to control-treated patients, respectively | Labeling | B | - | - | - | Bayer | 12/18/2003 | FALSE' |
| MESH:D006869 | 03/25/2004 | cipro | ciprofloxacin | Complicated UTI and pyelonephritis | Indicated for the treatment of complicated urinary tract infections (cUTIs) and pyelonephritis in pediatric patients 1 17 years of age Not drug of first choice due to increased adverse events compared to controls including events related to joints and/or surrounding tissues Information on PK and dose in pediatric patients 1 17 years of age The most frequent adverse events observed within 6 weeks of treatment initiation during the cUTI clinical trial were gastrointestinal 15% compared to 9% and musculoskeletal 9.3% compared to 6% in ciprofloxacin-treated compared to control-treated patients, respectively | Labeling | B | - | - | - | Bayer | 12/18/2003 | FALSE' |